Tourmaline Bio Profit Margin

Tourmaline Bio (TRML) currently reports a profit margin of -221185.0% as of June 2025. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore Tourmaline Bio's profit margin history and peer comparisons.

Tourmaline Bio's profit margin of -221185.0% is lower than the Healthcare sector average of 14.34%. That is roughly 1542019.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Tourmaline Bio's current -221185.0% should be judged against Healthcare norms (sector average: 14.34%) and against TRML's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -221185.0%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Tourmaline Bio, and consider following TRML for alerts when major investors trade the stock.

Tourmaline Bio is classified in the Healthcare sector. On profit margin, it currently shows -221185.0% versus a sector average near 14.34%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TRML with unrelated industries.